Back to Search
TSIPORAH SHORE, MD
MD
Medical Oncology Physician
NPI: 1720175813IndividualAccepts Medicare
Specialties, Licenses & Credentials
Internal Medicine Physician
Internal Medicine
Code: 207R00000X
214077(NY)
Hematology (Internal Medicine) Physician
Internal Medicine — Hematology
Code: 207RH0000X
214077(NY)
Medical Oncology PhysicianPrimary
Internal Medicine — Medical Oncology
Code: 207RX0202X
214077(NY)
CMS Specialties
PrimaryHEMATOPOIETIC CELL TRANSPLANTATION AND CELLULAR THERAPY
Additional
Education
OTHER
Class of 1979
Research & Publications (17)
Intensive treatment strategies may not provide superior outcomes in mantle cell lymphoma: overall survival exceeding 7 years with standard therapies.
PMID 18349031·Ann Oncol·2008
8-other
A study of a reduced-intensity conditioning regimen followed by allogeneic stem cell transplantation for patients with hematologic malignancies using Campath-1H as part of a graft-versus-host disease strategy.
PMID 16864057·Biol Blood Marrow Transplant·2006
3-trial
Clinical and ultrasonic evaluation of spleen size during peripheral blood progenitor cell mobilization by filgrastim: results of an open-label trial in normal donors.
PMID 19539214·Biol Blood Marrow Transplant·2009
3-trial
Randomized trial of high-dose chemotherapy with autologous peripheral-blood stem-cell support compared with standard-dose chemotherapy in women with metastatic breast cancer: NCIC MA.16.
PMID 18025439·J Clin Oncol·2008
4-observational
BiRD (Biaxin [clarithromycin]/Revlimid [lenalidomide]/dexamethasone) combination therapy results in high complete- and overall-response rates in treatment-naive symptomatic multiple myeloma.
PMID 17989313·Blood·2008
3-trial
Safety and tolerability of velafermin (CG53135-05) in patients receiving high-dose chemotherapy and autologous peripheral blood stem cell transplant.
PMID 17710442·Support Care Cancer·2008
3-trial
Stem cell mobilization with cyclophosphamide overcomes the suppressive effect of lenalidomide therapy on stem cell collection in multiple myeloma.
PMID 18541199·Biol Blood Marrow Transplant·2008
3-trial
Measurement of equity sensitivity: a comparison of the Equity Sensitivity Instrument and Equity Preference Questionnaire.
PMID 18481667·Psychol Rep·2008
4-observational
Effects of feedback accountability and self-rating information on employee appraisals: a replication and extension.
PMID 17886493·Psychol Rep·2007
8-other
Dose-attenuated radioimmunotherapy with tositumomab and iodine 131 tositumomab in patients with recurrent non-Hodgkin's lymphoma (NHL) and extensive bone marrow involvement.
PMID 17325895·Leuk Lymphoma·2007
3-trial
Subsequent therapy can be administered after tositumomab and iodine I-131 tositumomab for non-Hodgkin lymphoma.
PMID 16362977·Cancer·2006
4-observational
Combination antibody therapy with epratuzumab and rituximab in relapsed or refractory non-Hodgkin's lymphoma.
PMID 15955901·J Clin Oncol·2005
3-trial
An evaluation of the donor experience in the canadian multicenter randomized trial of bone marrow versus peripheral blood allografting.
PMID 15148494·Biol Blood Marrow Transplant·2004
3-trial
A randomized multicenter comparison of bone marrow and peripheral blood in recipients of matched sibling allogeneic transplants for myeloid malignancies.
PMID 12176866·Blood·2002
3-trial
Development and validation of a scale measuring attitudes toward smoking.
PMID 11059207·J Soc Psychol·2000
8-other
Gingival hyperplasia complicating acute myelomonocytic leukemia.
PMID 10730004·J Can Dent Assoc·2000
5-case
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 520 E 70TH ST # STARR-341
NEW YORK, NY 10021 - Phone
- (212) 746-2646
Quick Facts
- NPI
- 1720175813
- Entity Type
- Individual
- Gender
- Female
- Medicare
- Accepted
- Specialties
- 3
- Locations
- 1
- Years in Practice
- 47
- Publications
- 17
Are you this provider?
Claim Your Profile